Antisense p53 decreases production of VEGF in follicular thyroid cancer cells

Endocrine. 2006 Jun;29(3):409-12. doi: 10.1385/ENDO:29:3:409.

Abstract

Inactivating mutations of wild-type p53 (WTp53) tumor suppressor gene are common in anaplastic thyroid cancer (ATC) and are associated with poor prognosis. Mutated p53 (MTp53) has been implicated with angiogenesis. Therefore, the potential of MTp53 knockout by oligodeoxyribonucleotide phosphorothioates (ODNs) to affect VEGF production of undifferentiated thyroid cancer cells with a recessive MTp53 mutation was evaluated. Transient transfection with 20 bp ODNs complementary to portions of exon 10 of p53 and a negative control ODN (HIV-RT) were carried out in FTC-133 cells. In vitro secretion of VEGF protein was quantified by EIA and correlated to cell numbers, which was evaluated by in vitro MTT assay. Transfection of undifferentiated thyroid cancer cells with ODN reduced VEGF secretion of FTC-133 cells following transfection by 34% as compared to the negative control (cells transfected with ODN-HIV; p = 0.03). These results suggest that transient MTp53 knockout with ODNs complementary to p53 nucleotide sequences impair secretion of VEGF in the undifferentiated thyroid cancer cell line FTC-133.

Publication types

  • Comparative Study
  • Evaluation Study

MeSH terms

  • Adenocarcinoma, Follicular / metabolism*
  • Cell Survival
  • Gene Silencing / physiology*
  • Humans
  • Oligodeoxyribonucleotides, Antisense / metabolism
  • Oligodeoxyribonucleotides, Antisense / pharmacology
  • Thyroid Neoplasms / metabolism*
  • Transfection
  • Tumor Cells, Cultured
  • Tumor Suppressor Protein p53 / metabolism*
  • Vascular Endothelial Growth Factor A / biosynthesis*
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Oligodeoxyribonucleotides, Antisense
  • Tumor Suppressor Protein p53
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A